Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Bioverativ (BIVV) Stock Price

Media headlines about Bioverativ (NASDAQ:BIVV) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Bioverativ earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 45.6984634178866 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Bioverativ (NASDAQ BIVV) traded up $0.43 during mid-day trading on Wednesday, hitting $50.68. 782,429 shares of the stock were exchanged, compared to its average volume of 1,605,192. Bioverativ has a 52-week low of $40.00 and a 52-week high of $64.41.

Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.25. The business had revenue of $291.60 million during the quarter, compared to analyst estimates of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The company’s revenue for the quarter was up 27.2% on a year-over-year basis. equities research analysts forecast that Bioverativ will post 2.45 EPS for the current fiscal year.

Several research firms recently weighed in on BIVV. Jefferies Group reaffirmed a “buy” rating and set a $70.00 price objective (up previously from $67.00) on shares of Bioverativ in a research report on Wednesday, August 9th. Zacks Investment Research raised shares of Bioverativ from a “sell” rating to a “hold” rating in a report on Friday, August 18th. Deutsche Bank set a $53.00 target price on shares of Bioverativ and gave the stock a “hold” rating in a report on Monday, November 20th. Morgan Stanley reissued an “underweight” rating and issued a $47.00 target price (up previously from $45.00) on shares of Bioverativ in a report on Friday, October 6th. Finally, Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 target price for the company in a report on Wednesday, September 20th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $60.93.

TRADEMARK VIOLATION WARNING: “Somewhat Favorable Media Coverage Somewhat Unlikely to Affect Bioverativ (BIVV) Stock Price” was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The original version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/12/06/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-bioverativ-bivv-stock-price.html.

About Bioverativ

Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.

Insider Buying and Selling by Quarter for Bioverativ (NASDAQ:BIVV)

Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply